<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>NSAIDs and Upper GI Bleed</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Michelle Lin, MD</div><div><strong>Updated:</strong> <!-- -->7/15/2011</div></div><div class="card__content"><h1 id="nsaids-and-upper-gi-bleed">NSAIDs and Upper GI Bleed</h1>
<ul>
<li>Stomach and platelets have much more COX-1 receptors than COX-2 receptors.</li>
<li>Below are statistics from a systematic review on NSAIDs and upper GI complications (bleeding, perforation)</li>
</ul>
<h2 id="ketorolac">Ketorolac</h2>
<ul>
<li>Has the highest relative risk for upper GI complication = 14.54 (see below)</li>
<li>Before giving, first check that patients do NOT have a history of a GI bleed or peptic ulcer disease.</li>
</ul>
<h2 id="nsaid-induced-complications">NSAID-Induced Complications</h2>
<table>
<thead>
<tr>
<th><strong>NSAID Medication</strong></th>
<th align="center"><strong>Estimated Relative Risk of Complication</strong></th>
<th align="center"><strong>[95 % CI]</strong></th>
</tr>
</thead>
<tbody><tr>
<td>COX-1 Inhibitors (all)</td>
<td align="center">4.5</td>
<td align="center">[3.82-5.31]</td>
</tr>
<tr>
<td>- <span class="drug">Ibuprofen</span></td>
<td align="center">2.69</td>
<td align="center">[2.17-3.33]</td>
</tr>
<tr>
<td>- <span class="drug">Diclofenac</span></td>
<td align="center">3.98</td>
<td align="center">[3.36-4.72]</td>
</tr>
<tr>
<td>- <span class="drug">Meloxicam</span></td>
<td align="center">4.15</td>
<td align="center">[2.59-6.64]</td>
</tr>
<tr>
<td>- <span class="drug">Indomethacin</span></td>
<td align="center">5.40</td>
<td align="center">[4.16-7.00]</td>
</tr>
<tr>
<td>- <span class="drug">Ketoprofen</span></td>
<td align="center">5.57</td>
<td align="center">[3.94-7.87]</td>
</tr>
<tr>
<td>- <span class="drug">Naproxen</span></td>
<td align="center">5.63</td>
<td align="center">[3.83-8.28]</td>
</tr>
<tr>
<td>- <span class="drug">Piroxicam</span></td>
<td align="center">9.94</td>
<td align="center">[5.99-16.50]</td>
</tr>
<tr>
<td>- <span class="drug">Ketorolac</span></td>
<td align="center">14.54</td>
<td align="center">[5.87-36.04]</td>
</tr>
<tr>
<td>COX-2 Inhibitors (all)</td>
<td align="center">1.88</td>
<td align="center">[0.96-3.71]</td>
</tr>
<tr>
<td>- <span class="drug">Celecoxib</span></td>
<td align="center">1.42</td>
<td align="center">[0.85-2.37]</td>
</tr>
<tr>
<td>- <span class="drug">Aceclofenac</span></td>
<td align="center">1.44</td>
<td align="center">[0.65-3.2]</td>
</tr>
<tr>
<td>- <span class="drug">Rofecoxib</span></td>
<td align="center">2.12</td>
<td align="center">[1.59-2.84]</td>
</tr>
</tbody></table>
<h2 id="risk-factors-for-upper-gi-complication">Risk Factors for Upper GI Complication</h2>
<ol>
<li>Longer drug half-life</li>
<li>Slow-release formulation</li>
<li>Dual inhibition of COX-1 and COX-2 isoenzymes </li>
</ol>
<p>Relative risk is greatest when first starting medication (&lt;30 days)</p>
<h2 id="references">References</h2>
<ul>
<li>Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010 Jun;62(6):1592-601 [<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=20178131">PubMed</a>]</li>
</ul>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"nsaid-gi-bleed","title":"NSAIDs and Upper GI Bleed","authors":["Michelle Lin, MD"],"categories":[{"slug":"gastroenterology","name":"Gastroenterology"},{"slug":"pharmacology","name":"Pharmacology"}],"created":"2011/07/15","updated":null,"body":"\n# NSAIDs and Upper GI Bleed\n\n- Stomach and platelets have much more COX-1 receptors than COX-2 receptors.\n- Below are statistics from a systematic review on NSAIDs and upper GI complications (bleeding, perforation)\n\n## Ketorolac \n\n- Has the highest relative risk for upper GI complication = 14.54 (see below)\n- Before giving, first check that patients do NOT have a history of a GI bleed or peptic ulcer disease.\n\n## NSAID-Induced Complications\n\n| **NSAID Medication**                      | **Estimated Relative Risk of Complication** | **[95 % CI]** |\n| ----------------------------------------- | :-----------------------------------------: | :-----------: |\n| COX-1 Inhibitors (all)                    |                     4.5                     |   [3.82-5.31] |\n|  - \u003cspan class=\"drug\"\u003eIbuprofen\u003c/span\u003e    |                     2.69                    |  [2.17-3.33]  |\n|  - \u003cspan class=\"drug\"\u003eDiclofenac\u003c/span\u003e   |                     3.98                    |  [3.36-4.72]  |\n|  - \u003cspan class=\"drug\"\u003eMeloxicam\u003c/span\u003e    |                     4.15                    |  [2.59-6.64]  |\n|  - \u003cspan class=\"drug\"\u003eIndomethacin\u003c/span\u003e |                     5.40                    |  [4.16-7.00]  |\n|  - \u003cspan class=\"drug\"\u003eKetoprofen\u003c/span\u003e   |                     5.57                    |  [3.94-7.87]  |\n|  - \u003cspan class=\"drug\"\u003eNaproxen\u003c/span\u003e     |                     5.63                    |  [3.83-8.28]  |\n|  - \u003cspan class=\"drug\"\u003ePiroxicam\u003c/span\u003e    |                     9.94                    |  [5.99-16.50] |\n|  - \u003cspan class=\"drug\"\u003eKetorolac\u003c/span\u003e    |                    14.54                    |  [5.87-36.04] |\n| COX-2 Inhibitors (all)                    |                     1.88                    |  [0.96-3.71]  |\n|  - \u003cspan class=\"drug\"\u003eCelecoxib\u003c/span\u003e    |                     1.42                    |  [0.85-2.37]  |\n|  - \u003cspan class=\"drug\"\u003eAceclofenac\u003c/span\u003e  |                     1.44                    |   [0.65-3.2]  |\n|  - \u003cspan class=\"drug\"\u003eRofecoxib\u003c/span\u003e    |                     2.12                    |  [1.59-2.84]  |\n\n## Risk Factors for Upper GI Complication\n\n1. Longer drug half-life\n2. Slow-release formulation\n3. Dual inhibition of COX-1 and COX-2 isoenzymes \n\nRelative risk is greatest when first starting medication (\u0026lt;30 days)\n\n## References\n\n- Massó González EL, Patrignani P, Tacconelli S, García Rodríguez LA. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. Arthritis Rheum. 2010 Jun;62(6):1592-601 [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=20178131)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"nsaid-gi-bleed"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>